Literature DB >> 373911

Combination chemotherapy for advanced non-Hodgkin's lymphoma of unfavourable histology.

T A Lister, M H Cullen, R B Brearley, M E Beard, A G Stansfeld, J M Whitehouse, P F Wrigley, J M Ford, J S Malpas, D Crowther.   

Abstract

Thirty previously untreated adults with diffuse histiocytic and diffuse undifferentiated lymphoma were treated with a combination of adriamycin, vincristine, prednisolone, and L-asparaginase. Complete remission was achieved in 11 out of 12 cases with stage III and 7 out of 18 cases with stage IV disease (P less than 0.005). Bone marrow infiltration, clinical central nervous system involvement, and massive intra-abdominal disease all influenced the prognosis adversely. Complete remission was followed by cranial irradiation and intrathecal methotrexate, and maintained with weekly cyclophosphamide and methotrexate and daily 6-mercaptopurine. The duration of remission was significantly longer for patients with stage III disease (the median of which has not been reached), than for patients with stage IV disease (P = 0.007). Survival was significantly longer for patients in whom complete remission was achieved than for those in whom it was not (P = 0.001), and also for patients with stage III than for those with stage IV disease (P = 0.02).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 373911     DOI: 10.1007/bf00254044

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  16 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases.

Authors:  S E Jones; Z Fuks; M Bull; M E Kadin; R F Dorfman; H S Kaplan; S A Rosenberg; H Kim
Journal:  Cancer       Date:  1973-04       Impact factor: 6.860

3.  Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.

Authors:  P A Bunn; P S Schein; P M Banks; V T DeVita
Journal:  Blood       Date:  1976-01       Impact factor: 22.113

4.  Advanced diffuse histiocytic lymphoma, a potentially curable disease.

Authors:  V T DeVita; G P Canellos; B Chabner; P Schein; S P Hubbard; R C Young
Journal:  Lancet       Date:  1975-02-01       Impact factor: 79.321

5.  Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.

Authors:  R I Fisher; V T DeVita; B L Johnson; R Simon; R C Young
Journal:  Am J Med       Date:  1977-08       Impact factor: 4.965

6.  Cytological and functional criteria for the classification of malignant lymphomata.

Authors:  K Lennert; H Stein; E Kaiserling
Journal:  Br J Cancer Suppl       Date:  1975-03

7.  Membrane markers in "histiocytic" lymphomas (reticulum cell sarcomas).

Authors:  J C Brouet; J L Preud'Homme; G Flandrin; N Chelloul; M Seligmann
Journal:  J Natl Cancer Inst       Date:  1976-03       Impact factor: 13.506

8.  Combination chemotherapy for acute lymphoblastic leukaemia in adults.

Authors:  T A Lister; J M Whitehouse; M E Beard; R L Brearley; P F Wrigley; R T Oliver; J E Freeman; R K Woodruff; J S Malpas; A M Paxton; D Crowther
Journal:  Br Med J       Date:  1978-01-28

9.  Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.

Authors:  P S Schein; V T DeVita; S Hubbard; B A Chabner; G P Canellos; C Berard; R C Young
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391

10.  High-dose methotrexate in acute lymphocytic leukemia.

Authors:  A I Freeman; J J Wang; L F Sinks
Journal:  Cancer Treat Rep       Date:  1977-07
View more
  5 in total

1.  The need for prophylactic treatment to the central nervous system in patients with aggressive non-Hodgkin's lymphoma.

Authors:  C J Hawkey; P J Toghill
Journal:  Postgrad Med J       Date:  1983-05       Impact factor: 2.401

2.  A pilot study of cyclical chemotherapy with high-dose methotrexate and CHOP (MTX-CHOP) in poor-prognosis non-Hodgkin's lymphoma (NHL).

Authors:  J A Child; D L Barnard; S C Cartwright; I Lauder; A V Simmons; J Stone; J Thorogood
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology.

Authors:  C J Gallagher; A Copplestone; J D Meikle; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Minimal neuropsychological sequelae following prophylactic treatment of the central nervous system in adult leukaemia and lymphoma.

Authors:  J Tucker; P F Prior; C R Green; G M Ede; J F Stevenson; J Gawler; G A Jamal; M Charlesworth; C M Thakkar; P Patel
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

5.  New approaches to the management of patients with non-Hodgkin's lymphoma of high-grade pathology. First Gordon Hamilton-Fairley memorial lecture.

Authors:  D Crowther
Journal:  Br J Cancer       Date:  1981-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.